Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vascular function in patients with advanced heart failure and continuous-flow or pulsatile ventricular assist devices.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

Antibiotic prophylaxis before dental procedures to prevent infective endocarditis: a systematic review.

Infection·2022
Same author

Targeting SIRT1 Rescues Age- and Obesity-Induced Microvascular Dysfunction in Ex Vivo Human Vessels.

Circulation research·2022
Same author

Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort.

ESC heart failure·2022
Same author

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.

European journal of heart failure·2022
Same author

Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.

European journal of heart failure·2022

相关实验视频

Updated: May 1, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 16, 2010

45.2K

选择性COX-2抑制改善了冠状动脉疾病中的内皮功能.

Rémy Chenevard1, David Hürlimann, Markus Béchir

  • 1Cardiovascular Center, Cardiology and Department of Rheumatology, University Hospital Zürich, Switzerland.

Circulation
|January 29, 2003
PubMed
概括

选择性COX-2抑制,就像塞莱科西布一样,改善了冠状动脉疾病患者的血管功能和减少了炎症. 这表明这些药物对高危患者的潜在心血管益处.

更多相关视频

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

16.1K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.5K

相关实验视频

Last Updated: May 1, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 16, 2010

45.2K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

16.1K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.5K

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.
  • 炎症研究 炎症研究

背景情况:

  • 关于COX-2抑制剂与NSAIDs的心血管安全性的持续辩论.
  • 在高危患者中,需要评估选择性COX-2抑制对心血管疾病替代品,特别是内皮功能的影响.

研究的目的:

  • 确定选择性COX-2抑制对冠状动脉疾病患者内皮功能和炎症标志物的影响.

主要方法:

  • 这是一项双盲,安慰剂控制,交叉研究,涉及14名患有严重冠状动脉疾病的男性患者,他们在背景阿司匹林和他类药物治疗中.
  • 患者接受了赛莱科克西布 (200毫克两次) 或安慰剂2周.
  • 评估了流媒体臂动脉扩张,高灵敏度C反应蛋白,氧化LDL和前列腺素.

主要成果:

  • 与安慰剂相比,切莱科克西布显著改善了内皮依赖的血管扩张 (3.3%对2.0%,P=0.026).
  • 内皮独立的血管扩张保持不变.
  • 切莱科克西布降低了高灵敏度C反应蛋白 (1.3 mg/L与1.8 mg/L相比,P=0.019) 和氧化的LDL (43.6 U/L与47.6 U/L相比,P=0.028).

结论:

  • 这是第一个表明选择性COX-2抑制改善冠状动脉疾病患者内皮功能的研究.
  • 选择性COX-2抑制减少了慢性炎症和氧化应激.
  • 这些发现表明选择性COX-2抑制剂对心血管结果的潜在有益影响.